Comments
Glenmark Pharmaceuticals today said its subsidiary Glenmark Generics Inc has received final approval from the US health regulator for Verapamil tablets, which are used for treating hypertension.
“Today’s approval completes Glenmark’s marketing portfolio for the Verapamil extended-release product line,” Glenmark said in a statement.
The US Food and Drug Administration (USFDA) approval is for Verapamil extended release tablets in the strengths of 120 mg and 180 mg. The company had earlier received approval on the 240 mg dosage in September 2009, Glenmark said.
Verapamil extended-release tablets are generics of Isoptin SR tablets of Ranbaxy.
“Verapamil extended release tablets are indicated in the management of essential hypertension and for the 12 month period ending March 2011 achieved sales of $52 million, according to IMS Health,” it added.
The company has 72 generic products authorised for distribution in the US market and has over 35 ANDAs filed with the USFDA which are pending approval.
Shares of Glenmark were trading at Rs 338.40 in the afternoon trade on BSE, up 2.58 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.